Ammonia (NH3) is a colorless chemical compound comprised of nitrogen and hydrogen that is widely used in agriculture and in ...

Scientists at Johns Hopkins Medicine say results of a new National Institutes of Health-funded study are advancing efforts to ...

The BioMarin Pharmaceutical Inc. acquisition of Amicus Therapeutics, Inc. will likely be beneficial and accretive for both ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

A research team has managed to “bottle” a highly reactive carbene in water, overturning a major assumption in chemistry.

Researchers built a low-cost, automated system reusing enzymes & microbes with magnets to cut biofuel & food production costs ...

As a proof of concept, the engineers then used the same system to convert acetyl-CoA into malate, a commercially valuable ...

The global transition to a hydrogen-based clean energy economy faces a critical bottleneck: current proton exchange membrane ...

Palisade Bio's PALI-2108 could be a game-changer for gut health with strong upside potential. Read here for an investment analysis of PALI stock.

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

Iranian researchers discovered new bacteria, Bacillus spizizenii, that produce large amounts of a starch-breaking enzyme.

As of Friday, December 19, BioMarin Pharmaceutical Inc.’s BMRN share price has surged by 14.13%, which has investors questioning if this is right time to sell.